LivaNova (NASDAQ:LIVN) Issues FY25 Earnings Guidance

LivaNova (NASDAQ:LIVN) updated its FY25 earnings guidance on Tuesday. The company provided EPS guidance of $3.65-3.75 for the period, compared to the consensus EPS estimate of $3.66. The company issued revenue guidance of ~$1.316-1.329 billion, compared to the consensus revenue estimate of $1.33 billion. LivaNova also updated its FY 2025 guidance to 3.650-3.750 EPS.

LivaNova Price Performance

NASDAQ LIVN traded down $8.91 during trading on Tuesday, reaching $40.59. 1,016,669 shares of the company traded hands, compared to its average volume of 489,086. LivaNova has a 1-year low of $40.77 and a 1-year high of $64.47. The company has a market cap of $2.20 billion, a price-to-earnings ratio of 96.95 and a beta of 1.00. The stock’s 50 day moving average price is $47.94 and its two-hundred day moving average price is $49.64. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37.

Wall Street Analyst Weigh In

A number of analysts have weighed in on LIVN shares. Robert W. Baird upped their price target on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. StockNews.com raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a report on Friday, February 14th. Needham & Company LLC reissued a “buy” rating and set a $75.00 price target on shares of LivaNova in a report on Tuesday, January 28th. Finally, Mizuho reduced their price target on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, LivaNova currently has an average rating of “Buy” and an average price target of $69.17.

Insider Transactions at LivaNova

In related news, Director Francesco Bianchi sold 1,250 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the transaction, the director now owns 7,522 shares in the company, valued at $383,546.78. The trade was a 14.25 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.27% of the stock is owned by company insiders.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.